Pharming Group Q1 2026 Results: Joenja Growth Strengthens as RUCONEST Pressure Weighs on Revenue
Pharming Group Q1 2026 Results: Joenja Growth Strengthens as RUCONEST Pressure Weighs on Revenue
Pharming Group N.V. reported a mixed first quarter for 2026, with strong growth from its rare-disease medicine Joenja partly offset by weaker sales of RUCONEST. Total revenue fell 8% year over year to US$72.4 million, compared with US$79.1 million in the same period of 2025.
Joenja Delivers Strong Growth
Joenja revenue rose 34% to US$14.1 million in Q1 2026. Pharming said the growth was driven by more U.S. patients on paid therapy, stronger international demand, and continued uptake in markets such as the U.K. The company reported 127 U.S. patients on paid therapy as of March 31, 2026, up 25% from 102 patients one year earlier.
The company also highlighted progress toward broader access for Joenja, including work on U.S. pediatric label expansion and planned launches in Japan and Europe during 2026. This makes Joenja an increasingly important growth driver as Pharming shifts its business toward rare immune disorders and broader specialty medicine opportunities.
RUCONEST Sales Decline
RUCONEST revenue declined 15% year over year to US$58.4 million. Pharming said the decline was mainly caused by anticipated inventory drawdowns at U.S. specialty pharmacy customers, the company’s decision to withdraw RUCONEST from non-U.S. markets, and competitive pressure in the U.S. market.
Although RUCONEST remains Pharming’s largest revenue source, the first-quarter results show that the product is facing pressure as the company transitions toward newer products and pipeline assets.
Profitability and Cash Position
Gross profit decreased to US$65.8 million, compared with US$70.8 million in Q1 2025. Operating loss narrowed to US$4.9 million, versus US$7.0 million a year earlier. Net loss also improved sharply to US$5.2 million, compared with US$14.9 million in Q1 2025, helped by better finance results, favorable currency effects, and lower tax expense.
Pharming generated US$2.0 million in operating cash flow during the quarter, compared with US$0.2 million in Q1 2025. Cash, restricted cash, and marketable securities stood at US$171.8 million at the end of March 2026, down from US$181.1 million at the end of 2025. The decrease was mainly linked to a US$12.3 million lease settlement related to the early termination of the DSP facility lease in the Netherlands.
2026 Outlook Reaffirmed
Despite the revenue decline in the first quarter, Pharming reaffirmed its full-year 2026 revenue guidance of US$405 million to US$425 million. This suggests management still expects growth for the year, supported by Joenja expansion, international launches, and continued cost discipline.
The company’s outlook depends on balancing the decline of RUCONEST with stronger Joenja adoption and progress in its rare-disease pipeline. Investors will likely watch patient growth, regulatory updates, and second-half clinical data closely.
Business Update and Strategic Direction
Pharming’s Q1 2026 update shows a company in transition. RUCONEST is still the main commercial product, but Joenja is becoming more central to future growth. Management also pointed to clinical development work, including leniolisib studies in broader primary immunodeficiencies and continued progress with napazimone, also known as KL1333, in mitochondrial disease.
The key message from the quarter is clear: Pharming is not relying on one product forever. It is trying to build a broader rare-disease platform while managing pressure in its older franchise. That strategy may take time, but the growth in Joenja gives the company a stronger base for long-term expansion.
Market Reaction
Market reaction appeared negative after the report, with shares under pressure as investors focused on the revenue miss and RUCONEST decline. MarketBeat showed Pharming’s actual Q1 revenue of about US$72.45 million compared with expected revenue of US$92.06 million.
Still, the improved net loss, positive operating cash flow, and reaffirmed full-year guidance offered some support to the company’s longer-term story. The next major focus will be whether Joenja growth can accelerate enough to offset RUCONEST weakness in the coming quarters.
Conclusion
Pharming Group’s Q1 2026 earnings showed both challenge and progress. Revenue declined because of weaker RUCONEST sales, but Joenja delivered strong double-digit growth and continued to gain patients. The company also improved its net loss and maintained a solid cash position.
For 2026, Pharming’s success will depend on execution. If Joenja continues to grow, international launches move forward, and pipeline programs advance as expected, the company could strengthen its position in rare diseases. However, RUCONEST pressure remains a real challenge that investors will continue to monitor closely.
#PharmingGroup #Joenja #RUCONEST #BiotechNews #SlimScan #GrowthStocks #CANSLIM